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SUMMARY 
A timely immunization can be effective against certain diseases and can save thousands of lives. However, for some 
diseases it has been difficult, so far, to develop an efficient vaccine. Malaria, a tropical disease caused by a parasite of the 
genus Plasmodium, is one example. Bioinformatics has opened the way to new lines of experimental investigation One 
example is reverse vaccinology that aims to identify antigens that are capable of generating an immune response in a given 
organism using in silico studies. In this study we applied a reverse vaccinology methodology using a bioinformatics 
pipeline. We obtained 45 potential linear B cells consensus epitopes from the whole genome of P. falciparum 3D7 that can 
be used as candidates for malaria vaccines. The direct implication of the results obtained is to open the way to 
experimentally validate more epitopes to increase the efficiency of the available treatments against malaria and to explore 
the methodology in other diseases.  
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INTRODUCTION 
 
The first vaccine that was successfully tested in history was in 1796 when the 8-year-old child James Phipps was 
immunized against smallpox by Edward Jenner (1749-1823). He had observed that women who milked cows sometimes 
had hand injuries and did not develop the disease. After two years and after corroborating the results, Jenner published his 
findings [1]. He introduced the term vaccine derived from the latin word vaccinus ("cows"). Two hundred years after the 
discovery, smallpox is the first disease to be eradicated by humanity. 
Although it seemed risky at the time to try an experimental vaccine in a child, there was another famous test of a 
different vaccine in 1885 by Louis Pasteur (1822-1895). The 9-year-old child Joseph Meister avoided being the victim of 
rabies after a dog bit him [2]. These two examples show that a timely immunization can be effective against certain 
diseases.  
These two victories are always referenced in the field of vaccinology. However, the idea of immunity was already 
known from the time of Thucydides (430 B.C.). This was a result of his observations during the epidemic that occurred in 
Athens probably caused by typhoid fever. Thucydides realized that certain people who contracted the disease did not suffer 
a relapse although they were in direct contact with infected people [3].  These findings suggested that there might be a 
possibility of developing an immune response to various diseases.  
Bioinformatics [4, 5] has allowed both the development of new computational tools and suggested new lines of 
experimental investigation. To this must be added the fact that currently it is possible to sequence an entire genome in a 
matter of hours thanks to the use of solid-state nanopore sequencing as Erika Hayden demonstrated in her work published in 
Nature in 2012 [6]. According to NCBI data as those of October 2015, almost fourteen thousand genomes have been 
sequenced, of which 420 are from the archaea domain, 7,087 are bacterial, 1,551 are eukaryotic, and 4,845 of the viral type. 
Thus, there is a wide range of genetic information that would allow us to identify, for example, those antigens that may 
be useful for vaccine development, i.e. the reverse vaccinology methodology. 
Reverse vaccinology 
The concept of reverse vaccinology was introduced just a decade ago [7]. Its challenge is to identify those antigens that 
are capable of generating an immune response in a given organism using in silico studies. This new approach stems from 
the fact that a genome can be visualized as a "catalog" of those antigens that a pathogen can express. Therefore, the genome 
itself has all the information necessary to generate a vaccine. 
The first successful example was against the pathogen Neisseria meningitidis serogroup B (hereafter abbreviated 
MenB) that is commonly known as meningococcus [8, 9], for which a vaccine was obtained from genome analysis after 
forty years of trials. 
The 13 meningococcal serogroups have been identified (abbreviated as A, B, C, D, X, Y, Z, 29E, W135, H, I, K, and L) 
of which only five can cause epidemics (A, B , C, W135, and Y). Today, vaccines have been implemented for four of them. 
Unfortunately, the serogroup B one was not effective. This was due to the variation in the sequence of its protein surface 
and cross-reactivity of the capsular polysaccharide of the serogroup with human tissues [8]. In Venezuela, for example, 
outbreaks caused by meningococcus in 1998 with 132 cases and 26 deaths, were reported. A year later, the number of cases 
decreased but with similar number of deaths as the previous year. 
 
The manufacture of a MemB vaccine was possible by sequencing the genome of the strain MC58. Eighteen months 
after the entry, 570 ORFs (Open Reading Frame) that can be considered potentially antigenic were identified by using 
bioinformatics tools. Subsequently, some studies in the laboratory were started where only 350 could be expressed in E.coli. 
Once all of them were purified, they were injected into mice in order to examine the antiserum using ELISA and FACS  to 
assess the cellular localization of antigens in meningococcus. 
Finally, five proteins (called antigens of Neisseria), having a cross-protection against heterologous strains were 
obtained. Given the success of being able to obtain a vaccine against MenB, this technique is currently being used on other 
pathogens such as Bacillus anthracis [10], Streptococcus pneumoniae [11], Staphylococcus aureus [12, 13], Chlamydia 
pneumoniae [14], and Mycobacterium tuberculosis [15]. 
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Where do we start?  
The first step is to identify the function and location of the genes in the genome. In case they were not listed, both its 
location and its function should be predicted. To do so, Glimmer [16], Orpheus [17], and ORF Finder [18] applications are 
mainly used. Then, an alignment of all existing sequences in the genome must be performed. There are various 
computational methods specifically designed for alignment between pairs of sequences, the best known is Blast (available at 
http://blast.ncbi.nlm.nih.gov). It uses a heuristic approach and was originally implemented by Altschul et al in 1990 [20].  In 
that sense, the database of the National Center for Biotechnology Information [19] counts on 188,372,017 loci until October 
2015 (version 210.0), with a total of 202,237,081,559 of pairs. 
At this point, it is also important to consider the scientific computing time required to compare multiple sequences at 
once. As an example, it should be mentioned that the calculation conducted by the Argonne National Laboratory in which a 
supercomputer with more than ten thousand processors for simultaneous calculation was used [21]. The aim of the 
calculation was to identify all the sequences of microbial genomes that were similar to each other and to infer the function 
of those that were listed as hypothetical or unknown. However, the comparison information generated a volume of several 
Petabytes of data, i.e. the equivalent of having interconnected twenty five thousand 40 GB hard disks. 
In 2011, it was published the excellent performance achieved by the program mpiBLAST supercomputer BlueGene/P 
for multiple alignments using genes involved in the Influenza A (H1N1) from the NCBI in Proceedings of the European 
Computing Conference [22]. In this work, those hypothetical genes that so far had not been recorded were identified. 
This latest achievement introduces us to the subject of comparative genomics, i.e. the area that identifies regions of 
similarity that may exist between genomes. If all of the genes from different strains of the same species are analyzed, all the 
resulting information would allow us to identify the antigenic proteins that are similar to each other. With this, a wide range 
vaccine could be obtained, without restriction of a certain stock or region. 
Günter Blobel reported that proteins have intrinsic signals that govern the transportation and their location within the 
cell [23]. It has also been demonstrated that the role of signal peptides when certain motifs (i.e. a very specific combination 
of amino acids) are required for the secretion of certain proteins. In that sense, Bendtsen et al. [24] conducted a review of 
different computer programs that can predict signal peptides, resulting that the most used program was SignalP [25]. 
It is also noteworthy to state that the epitopes from an amino acid sequence can be obtained. Several computer 
programs (for example Antigenic, EMBOSS, ABC-pred, Bcepred, BepiPred, SYFPEITHI and so on) are available. 
However, the main problem is the large number of false positives that are predicted with them.  Such as the case of 
chromosome 1 of Plasmodium falciparum 3D7, where the result indicated of these predictions do not match with the data 
obtained by experimental methods [26].  
Why malaria? 
Currently, it is known that malaria is a tropical disease caused by a parasite of the genus Plasmodium through the bite 
of an infected Anopheles gambiae mosquito. Out of the 380 species of this type of mosquito, a little over 15% are 
responsible for transmitting the disease [27]. So far, 172 species of Plasmodium are known and of these, only five different 
strains affect the human species: P. falciparum, P. vivax, P. ovale, P. malariae and recently, P. knowlesi. In fact, the first 
recorded case of P. knowlesi occurred in 1965 in the United States that was linked to a traveler returning from Malaysia 
[28]. However, of the five strains mentioned, P. falciparum is the most virulent: half of its victims, sadly, are children under 
five. 
Reviewing the scientific literature, it is referenced that in Venezuela in 1854, Luis Daniel Beauperthuy (1807-1881) 
published the hypothesis that mosquitoes were the probable vectors of malaria and yellow fever in the journal Gaceta de 
Cumana [29]. Unfortunately, that work was not sufficiently disseminated.  In 1880, Charles Louis Alfonso Laveran (1845-
1922) discovered a parasite in human blood by examining soldiers in Algeria which called hematozoa of Laveran. 
Seventeen years later, Ronald Ross (1857-1932) stated that the mosquito is a transmitting agent when he was studying 
malaria in birds. In1899, the Italian Giovanni Battista Grassi (1854-1925) identified Anopheles as responsible for its 
transmission [30]. Unfortunately, the work performed in Venezuela by Beauperthuy remains unnoticed.  
Is it possible to develop a vaccine against malaria?  
To date, there has not been an effective response to this scourge. Ruth Nussenzweig et al. published in 1967 a work in 
which it was showed that it was possible to protect against malaria sporozoites when inoculating P. berghei irradiated with 
X-rays in rodents [31].  
It should be also noted the work in which a vaccine in humans was developed and tested in 1987 by the scientific team 
led by Manuel E. Patarroyo in Colombia. The vaccine, called SPf66, consisted of a mixture of three merozoite antigens 
[32]. Patarroyo and his collaborators showed an efficacy of 75% of the vaccine at the time of the phase I, while the results in 
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phases II and III ranged between 38% and 60%. Later the Patarroyo team conducted a test in Gambia which unfortunately 
did not meet their expectations. In the Bolivarian Republic of Venezuela, the team led by Oscar Noya performed similar 
tests in 1994 and found that SPf66 had a 55% of efficacy against strains of P. falciparum [33]. Even today this is the subject 
of scientific research in Colombia and the rest of the world. 
Currently, 17 vaccines are being tested. The biggest hopes are pinned on a vaccine called RTS,S/AS02, which proved 
to be safe and, in turn, resulted in a decrease in the number of clinical episodes by 30%, according to the trial in 
Mozambique in 2009 with 2,022 children aged between one and four years. The protection period amounts to 45 months 
[34]. 
 
As indicated above, the feasibility of potential antigens from genomic information to apply new vaccine candidates 
against malaria will be elucidated, thanks to the success of reverse vaccinology. 
 
MATERIALS AND METHODS 
 
In this paper, the methodology is applied to malaria, but it is possible to used it in other diseases as well.  For each 
protein found in the genome of P. falciparum 3D7, three conditions must be met simultaneously for its eventual selection as 
a potential vaccine candidate. First, those who have at least a transmembrane domain are chosen. Usually the TMHMM 
program (Transmembrane Helices in Proteins, available at http://www.cbs.dtu.dk/services/TMHMM/) is used [35]. Second, 
the resulting candidates are evaluated with the SignalP-NN program (available at http://www.cbs.dtu.dk/services/SignalP-
2.0/) with the restriction that two threshold values corresponding to MaxS and MeanS equal to 0.82 and 0.52, respectively 
must be exceeded [25]. The last condition is that the final result should be referred in the database called IEDB (available at 
http://iedb.org).   
Simultaneously, a series of consensus epitopes derived from linear B cells obtained from in silico genome-wide 
analysis of P. falciparum 3D7 will be selected according to Isea methodology [36-39], it means, all present peptide epitopes 
are mined in the IEDB database. Subsequently, the Redundancy program available at ExPASy (Protein Analysis Expert 
System, available at http://expasy.org/tools/redundancy/) is used for discarding those that are repeated. The remaining 
epitopes are analyzed using the Nomad program (available at http://expasy.org/tools/nomad.html). The latter program 
performs a local multi-alignment without allowing a gap between different amino acids that make up these epitopes; those 
compounds are also identified by blocks of 12 amino acids with greater likelihood between them, thanks to the iterative 
evaluation of an entropy function defined in the work of Hernandez et al. [40]. Lately, the obtained results are evaluated 
with a program called BepiPred for predicting B-cell epitopes in order to evaluate the final antigenicity [31]. That way, 
those linear B cells consensus epitopes that can be used to develop vaccines against malaria are obtained. 
RESULTS 
  
 The prediction of an epitope-based computational vaccine has already provided significant results. In this sense, this 
methodology is crucial when there is no effective drug available, in which this novel approach regarding epitope prediction 
for vaccine development is designed. Table 1 shows those proteins which satisfy the three aforementioned conditions set in 
the materials and methods section on each chromosome, and shows the number of antigenic proteins indicated inside the 
parenthesis.  
Finally, by analyzing all the peptide epitopes present in the IEDB database, hundreds of consensus epitopes are 
generated after applying the reduction and alignments using respectively the Redundancy and Nomad programs. After 
evaluating all of them with the BepiPred program, only 45 possible linear B cell epitopes are obtained, which are shown in 
Table 2.  However, it is necessary to implement in vivo studios that allow us to determine the optimal  B cell epitopes  
between 11 to 15. 
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Table 1. Those antigenic proteins that are present in P. falciparum 3D7 are shown. They should also exhibit at least one 
transmembrane domain and exceed the threshold values of the SignalP-NN program.  Inside the parenthesis the number of 
antigenic proteins is indicated. 
 
Chromosome 1 PFA0385w (1), PFA0690w (7), PFA0055c (7), PFA0125c (5), PFA0635c (1) 
Chromosome 2 PFB0400w (1), PFB0760w (21), PFB0205c (3),PFB0925w (1)  
Chromosome 3 PFC0490w (8), PFC0710w (7), PFC0125w (9), PFC0210c (337), PFC0590c (3) 
   PFC0835c (1), PFC0925w (1), PFC0810c (1), PFC1090 (7) 
Chromosome 4 PFD0260c (3), PFD0295c (7), PFD0110w (21), PFD0075w (1), PFD0210c (1), 
   PFD0440w (3), PFD0310w (17), PFD0690c (1), PFD0940w (8), PFD0555c (3), 
   PFD1195c (7), PFD1037w (207) 
Chromosome 5 PFE0120c (5), PFE0710w (1), PFE1330c (1),  PFE1510c (3)  
Chromosome 6 PFF0050c (1), PFF0620c (21), PFF0795w (7), PFF0800w (207), PFF0985c (1) 
   PFF1395c (2), PFF0995c (3), PFF1455c (1),  PFF1535w (7), PFF1475c (1) 
Chromosome 7 MAL7P1.3 (7), PF07_0061 (24), MAL7P1.102 (1), MAL7P1.203 (1), 
   PF07_0100 (1), PF07_0113 (3), MAL7P1.119 (1), MAL7P1.176 (35) 
Chromosome 8 PF08_0068 (1), MAL8P1.101 (10), PF08_0063 (214), PF08_0052 (1) 
   PF08_0008 (1), PF08_0050 (3), PF08_0011 (2), PF08_0005 (1)  
Chromosome 9 PFI0380c (3), PFI0210c (7), PFI0795w (7), PFI0640c (1), PFI0900w (7) 
   PFI1145w (208), PFI0960w (3),  PFI1475w (1817), PFI1730w (11),  PFI0920c (1) 
Chromosome 10 PF10_0018 (1), PF10_0053 (1), PF10_0166 (1), PF10_0168 (7),  
   PF10_0303 (2), PF10_0313 (3), PF10_0355 (5), PF10_0356 (60), 
   PF10_0392 (1)  
Chromosome 11 PF11_0023 (7), PF11_0064 (21), PF11_0224 (13), PF11_0229 (7) 
   PF11_0246 (21), PF11_0256 (7), PF11_0344 (35), PF11_0348 (21) 
   PF11_0381 (214), PF11_0486 (9), PF11_0503 (7)  
Chromosome 12 PFL0600w (2), PFL0070c (1), PFL0655w (7), PFL0765w (1), 
   PFL1060c (7), PFL1045w (4), PFL1415w (7), PFL1835w (207) 
   PFL2510w (1), PFL2505c  (1) 
Chromosome 13 PF13_0066 (3), MAL13P1.60 (13), PF13_0133 (1), MAL13P1.193 (2) 
   MAL13P1.210 (1), MAL13P1.203 (1), PF13_0265 (3), MAL13P1.262 (10) 
   PF13_0277 (1), MAL13P1.285 (1), MAL13P1.410 (207), MAL13P1.319 (3) 
   MAL13P1.342 (1), MAL13P1.465 (7) 
Chromosome 14 PF14_0005 (3), PF14_0016 (7), PF14_0045 (1), PF14_0063 (3),  
   PF14_0116 (3), PF14_0199 (21), PF14_0201 (1), PF14_0249 (1), 
   PF14_0250 (1), PF14_0275 (7), PF14_0318 (1), PF14_0342 (1), 
   PF14_0372 (32), PF14_0415 (1), PF14_0440 (1), PF14_0495 (6), PF14_0541 (1) 
 
 
Tabla 2.  Linear B cells consensus epitopes after a full in silico analysis of the P. falciparum 3D7 genome. 
NGNRHVPNSEDR  QIEEIKKETNQI TSDLEKKNIPDL 
AENVKPPKVDPA  QKYSSPSDINAQ SRNNHPQNTSDS 
QQQSEKKSISKV  YNNNLERGLGSG ELDGSKNEWGWS 
HSNSTTTSLNNN  DLDEPEQFRLPE ELSSGSSSLEQH 
EQEIKNKSLEEK GRNNENRSYNRK QQPEYEPSVHSI 
AEQTESPELQSA LHSDASKNKEKA LPKREPLDVPDE 
ELQSAPENKGTG NRNENNQNTDPY HNEDVREEIEEQ 
FPNHLPEELRKQ LSTNLPYGKTNL NTSDSQKECTDG 
SMNNHKDDMNNY EIKEKKEDLENL NLEDINKNTRND 
SPKVLDNERKQS NAETNPKGKGEV QHGHMHGSRNNH 
FDETLGEEDKDL EEERCLPKREPL DELDYANDIEKK 
PLDNIKDNVGKM SANKPKDELDYA YIDDVDRDVENY 
KNQLAGKDEYEA TLGEEDKDLDEP ENNDQKKDMEAQ 
ELRKQTKGVELQ EWSPCSVTCGKG EKKNENKNVSNV 
MPNDPNRNVDEN KLEETNKEYTNL SEESHSKTIDPS 
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CONCLUSIONS 
 
By using new computational methodologies that are able to predict new antimalarial vaccines, several advances can be 
achieved. An outcome could be to extend the period of protection of 45 months obtained with the experimental vaccine 
RTS,S/AS02.    
Epitopes-based vaccines have proven of high utility and can increase the efficiency of the available methods against 
malaria. To accomplish this work, the selection of those proteins of antigenic importance was restricted according to three 
basic requirements: a) at least one transmembrane domain must be present; b) values higher than the thresholds set out in 
the SignalP-NN program must be obtained; and, c) there must be some antigenic evidence published in scientific literature. 
Thus, about one hundred sequences can be used to develop a vaccine candidate, from over the five thousand ones available 
throughout the genome of P. falciparum 3D7 (see Table 1). 
After that, 45 potential linear B cells consensus epitopes with an antigenic behavior are obtained with the 
aforementioned process. Future work would define what criteria should be used to select the length of the consensus 
epitopes, the analysis of which was restricted to 12 residues, but can range between 11 and 15.  Finally experimental tests 
are necessary to determine the usefulness of this simple computational methodology.   is to open the way to experimentally 
validate more epitopes as derived vaccines against malaria. Epitopes-based vaccines have proven of high utility and can 
increase the efficiency of the available methods against malaria. 
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